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Abstract
Introduction: Methotrexate (MTX) enters cells via the reduced folate carrier SLC19A1, suggesting that SLC19A1 is
associated with the efficacy of MTX. We here examined the relationship between the efficacy of MTX and the
expression of SLC19A1 in glucose 6-phosphate isomerase (GPI)-induced arthritis. We found that interleukin-6 (IL-6)
regulated the expression of SLC19A1, so we studied the effect of a combination of MTX and anti-mouse IL-6
receptor antibody (MR16-1).
Methods: GPI-induced arthritis was induced by intradermal immunization with recombinant GPI. MTX was given
from the first day of immunization. Mice were injected once with MR16-1 10 days after immunization. The levels of
SLC19A1 mRNA in whole hind limbs and immune cells were measured. Synovial cells from arthritic mice were
cultured with cytokines, and cell proliferation and gene expressions were measured.
Results: MTX inhibited the development of GPI-induced arthritis; however, the efficacy of MTX gradually
diminished. SLC19A1 expression in immunized mice with arthritis was lower than in intact mice; moreover,
SLC19A1 expression in arthritic mice was further decreased when they were treated with MTX. IL-6 was highly
expressed in whole hind limbs of arthritic mice. In an in vitro study using synovial cells from arthritic mice, IL-6 +
soluble IL-6 receptor (sIL-6R) weakened the anti-proliferative effect of MTX and reduced SLC19A1 expression.
Finally, although MR16-1 did not improve arthritis at all when administered on day 10, MTX in combination with
MR16-1 more potently reduced the development of arthritis than did MTX alone. When used in combination with
MTX, MR16-1 apparently reversed the decrease in SLC19A1 induced by MTX alone.
Conclusions: In the present study, we demonstrated for the first time that IL-6 reduced the efficacy of MTX by
decreasing the expression of SLC19A1, which is important for MTX uptake into cells.
Introduction
Methotrexate (MTX) is an anchor drug for the treatment
of rheumatoid arthritis (RA) because of its efficacy, accep-
table safety, and cost. MTX is used in monotherapy or in
combination with either biological agents or other small
molecule anti-rheumatic drugs [1-3]. Regarding its anti-
rheumatic mechanisms, it has been reported that MTX
promotes adenosine release, inhibits pro-inflammatory
cytokine production, suppresses lymphocyte proliferation,
and reduces serum immunoglobulin via the inhibition of
folic acid metabolism [4-6]. However, loss or reduction of
its efficacy is a major problem in the treatment of RA. The
efficacy of MTX varies among treated patients, and
approximately 30% of patients discontinue administration
within one year [7-9].
Transporters play important roles in drug disposition
through their involvement in the pathways of drug
absorption, distribution, and excretion, and would be
among the major determinants of the pharmacological
and/or toxicological effects of drugs. The ubiquitously
expressed reduced folate carrier SLC19A1 is considered
the major transport route for MTX [10,11]. As MTX
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cannot pass through the plasma membrane because of
the anionic nature of MTX, SLC19A1-mediated cellular
uptake should be regarded as the first step in the mode
of action of MTX [12-14]. Previous studies using malig-
nant cells showed that resistance to MTX is associated
with reduced expression and activity of SLC19A1 [15,16].
However, the relationship between the efficacy of MTX
and the expression of SLC19A1 in arthritic animals and
RA patients is not fully understood.
Glucose 6-phosphate isomerase (GPI)-induced arthri-
tis is widely studied, not only for the understanding of
the pathogenesis of RA, but also for the development
of new therapeutics, because its pathological features
are similar to those of RA with pannus formation, car-
tilage or bone erosions, and angiogenesis in the syno-
vium [17]. Moreover, it has been reported that
cytotoxic T-lymphocyte antigen 4 immunoglobulin
fusion protein (CTLA-4Ig) and antibodies to tumor
necrosis factor- a (TNF-a) and IL-6, which are very
effective in the treatment of RA patients [18-20], also
show therapeutic effects in GPI-induced arthritis [21].
However, the efficacy of MTX has not yet been evalu-
ated in this model.
In the present study we examined the relationship
between the efficacy of MTX and the expression of
SLC19A1 in GPI-induced arthritis. We found that IL-6
regulated the expression of SLC19A1, so we also studied
the effect of concomitant use of MTX and anti-IL-6
receptor (IL-6R) antibody in this arthritis model.
Materials and methods
Animals
Male DBA/1J mice were purchased from Charles River
Japan (Yokohama, Japan). The mice were specific patho-
gen-free and were kept in cages in a room maintained at
20 to 26°C at a relative humidity of 35 to 75%. The
experimental protocol was approved by the Institutional
Animal Care and Use Committee of Chugai Pharmaceu-
tical Co., Ltd.
Induction of glucose-6-phosphate isomerase-induced
arthritis
GPI-induced arthritis was induced as previously
described, with modifications [21]. In brief, male DBA/
1J mice (6 weeks old) were immunized intradermally at
the base of the tail with 300 μg of recombinant GPI-glu-
tathione S-transferase fusion protein (GPI-GST) emulsi-
fied with an equal volume of complete adjuvant H37Ra
(DIFCO, Detroit, MI, USA). Pertussis toxin (200 ng/200
μL) was injected on the day of immunization and 2 days
after immunization. Clinical symptoms of arthritis were
evaluated visually and assigned a scale of 0 to 3 for each
limb (maximum score/mouse = 12).
Treatment regimen
MTX (Sigma Aldrich, St Louis, MO, USA) dissolved in 7%
sodium bicarbonate solution was given orally 3 times a
week from the first day of immunization. Ten days after
immunization, mice were intraperitoneally injected once
with 4 mg of rat anti-mouse IL-6R monoclonal antibody,
MR16-1 [22]. The vehicle group mice were administered
7% sodium bicarbonate solution orally, and were intraperi-
toneally injected with phosphate buffer saline (PBS). The
MTX group mice were administered MTX orally, and
were intraperitoneally injected with PBS. The MR16-1
group mice were administered 7% sodium bicarbonate
solution orally and were intraperitoneally injected with
MR16-1. The MTX plus MR16-1 group mice were admi-
nistered MTX orally and were intraperitoneally injected
with MR16-1. Each group consisted of 8 or 9 animals.
Analysis of gene expressions in mouse whole hind limbs
Immediately after the animals were killed, whole hind
limbs were immersed in RNAlater RNA Stabilization
Reagent (Qiagen, Valencia, CA, USA) and stored at -80°
C until total RNA extraction. The whole hind limbs
were excised, immediately soaked in TRIzol (Invitrogen,
Carlsbad, CA, USA), and crushed in a bead mill (Tissue-
Lyser II; Qiagen, Valencia, CA, USA). Total RNA was
extracted using an RNeasy kit (Qiagen) according to the
kit manufacturer’s protocol. Amounts of total RNA
obtained from a single whole hind limb were 4.5 to 18
μg (intact mice), 15to 60 μg (non-treated immunized
mice), 9 to 60 μg (MTX-treated immunized mice), 12 to
30 μg (MR16-1-treated immunized mice), and 4.2 and
30 μg (MTX- and MR16-1-treated immunized mice).
cDNA was synthesized with an Omniscript RT kit (Qia-
gen) using random 9-mer primers (TaKaRa, Shiga,
Japan) according to the kit manufacturer’s protocol.
Quantitative real-time polymerase chain reaction (PCR)
was performed by running a TaqMan gene expression
assay (Applied Biosystems, Foster City, CA, USA), tar-
geting mouse SLC19A1, IL-6, TNF-a, and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), on an ABI
PRISM 7500 system (Applied Biosystems) according to
the manufacturer’s protocol.
Analysis of gene expressions in mouse immune cells
For CD4 T cell and B cell subset sorting, splenocytes
were labeled with antibodies to CD4 and B220 and sorted
to 97% purity by using a fluorescence-activated cell sorter
(FACSAria III; BD Biosciences, Franklin Lakes, NJ, USA).
Total RNA was extracted using an RNeasy kit (Qiagen)
according to the kit manufacturer’s protocol. Synthesis of
cDNA and measurement of mRNA levels by quantitative
real-time PCR were performed by the same methods as
described above.
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Isolation and culture of mouse synovial cells
Arthritic mice were killed and the synovial tissues
removed from their hind limbs. Synovial tissues were incu-
bated at 37°C for 180 min in a-MEM supplemented with
10% fetal bovine serum (FBS) and containing 0.5 mg/mL
of Liberase Blendzyme2 (Roche Diagnostics, Basel, Swit-
zerland). After incubation of the synovial tissues with the
Liberase Blendzyme2, the resulting cells were cultured in a
culture flask in a-MEM supplemented with 10% FBS and
the non-adherent cells were removed and discarded. Syno-
vial cells were then subcultured in a-MEM supplemented
with 10% FBS to a density of 2 × 105 cells/35 mL in a
T175 flask. In this study, synovial cells from passages two
to five were used.
Analysis of gene expressions in synovial cells
Synovial cells (5 × 104 cells/2 mL/well) were cultured in
a-MEM supplemented with 10% FBS for 24 h. After
this pre-culture, cells were cultured with mouse IL-6
(Peprotech, Rocky Hill, NJ, USA) and soluble mouse IL-
6R (R&D Systems, Minneapolis, MN, USA), TNF-a, or
MTX for 24 h. Total RNA was extracted using an
RNeasy kit (Qiagen) according to the kit manufacturer’s
protocol. cDNA was synthesized with an Omniscript RT
kit (Qiagen) using random 9-mer primers (Takara)
according to the kit manufacturer’s protocol. Quantita-
tive real-time PCR was performed by running a TaqMan
gene expression assay, targeting mouse SLC19A1, multi-
drug resistance protein-1 (MRP-1), breast cancer resis-
tance protein (BCRP), and GAPDH, on an ABI PRISM
7500 system (Applied Biosystems) according to the
manufacturer’s protocol.
Proliferation assay
Synovial cells (5 × 103 cells/0.2 mL/well) were cultured
either with medium alone or with mouse IL-6, mouse sIL-
6R, and MTX in a 96-well flat bottom plate for 3 days.
Synovial cell proliferation was assessed using the Cell
Proliferation ELISA system (GE Healthcare UK, Buckin-
ghamshire, UK) according to the manufacturer’s instruc-
tions. Briefly, bromodeoxyuridine (BrdU) was added for the
last 3 h, and its uptake was detected with anti-BrdU anti-
body. Substrate was added to elicit a colorimetric reaction,
and absorbance at 450 nm was measured using a micro-
plate reader (SLT Inc., Salzburg, Austria). The data are
expressed in terms of optical density (OD) values.
Measurement of the uptake of MTX
Synovial cells (5 × 104 cells/2 mL/well) were cultured for
24 h in a-MEM supplemented with 10% FBS. After this
pre-culture, cells were cultured with mouse IL-6 and
mouse sIL-6R for an additional 24 h. After washing cells
with PBS, cells were incubated in the presence 100 nM of
Alexa Fluor 488 conjugated MTX (Invitrogen) for 5 h.
After incubation, cells were treated with trypsin-EDTA
(Gibco, Grand Island, NY, USA) to obtain a single cell
suspension. Intracellular accumulation of MTX was mea-
sured with a fluorescence-activated cell sorter (FACS-
Canto II; BD Biosciences) and calculated mean
fluorescence intensities (MFIs) were analyzed using
FACSDiva software (BD Bioscience).
Measurement of cytokine levels in serum
Serum samples were collected 15 days after immuniza-
tion, and the concentrations of serum amyloid A (SAA)
and IL-6 were measured by SAA mouse ELISA kit (Invi-
trogen) and Mouse IL-6 Quantikine ELISA Kit (R&D
systems), respectively.
Statistical analysis
Statistical significances were estimated by Wilcoxon’s test,
unpaired t-test, and Dunnett’s multiple comparison test
using a statistical software package (SAS Institute Japan,
Tokyo, Japan), with the significance level set to 5%.
Results
Efficacy of MTX, and SLC19A1 expression in GPI-induced
arthritis
MTX was administered orally 3 times a week for 4
weeks. MTX (10 mg/kg) suppressed the progression of
arthritis, but from day 20 its efficacy gradually dimin-
ished (Figure 1A).
The mRNA expressions of SLC19A1 in whole hind
limbs and immune cells were examined 15 days after
immunization (peak of arthritis). The SLC19A1 expres-
sion in immunized mice was lower than that in intact
mice (Figure 1B-D). Moreover, the expression level of
SLC19A1 in whole hind limbs was further decreased by
treatment with MTX (Figure 1B). TNF-a and IL-6
mRNA expressions in whole hind limbs were up-regu-
lated in immunized mice with arthritis compared with
intact mice, and MTX treatment did not reduce TNF-a
or IL-6 mRNA expressions (Figure 1E, F). IL-1 mRNA
expression was not detectable (data not shown).
Effect of MTX and IL-6 on the expression of SLC19A1 in
synovial cells
We examined the effects of MTX, TNF-a and IL-6 on
the expression of SLC19A1 in synovial cells. IL-6 or sIL-
6R alone did not affect SLC19A1 mRNA expression (data
not shown), but IL-6 + sIL-6R significantly decreased
SLC19A1 expression in synovial cells (Figure 2A). MTX,
but not TNF-a, significantly decreased the expression of
SLC19A1 in synovial cells (Figure 2B, C). Moreover, in
the presence of IL-6 + sIL-6R, MTX further reduced
SLC19A1 expression (Figure 2D).
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To investigate if MTX and IL-6 + sIL-6R affected the
accumulation of MTX in synovial cells, the synovial
cells were pre-treated with MTX and IL-6 + sIL-6R, and
then MTX uptake into cells was examined. As shown in
Figure 2E, pre-treatment with IL-6 + sIL-6R, or with
MTX, reduced the accumulation of fluorescent conju-
gated MTX in synovial cells, and pre-treatment with IL-
6 + sIL-6R + MTX further reduced the accumulation of
fluorescent conjugated MTX in synovial cells.
Effect of IL-6 on MTX-induced anti-proliferative effect
Because we previously reported that MTX suppressed the
proliferation of synovial cells from RA patients [23], we
examined the effect of IL-6 + sIL-6R on MTX-induced
suppression of proliferation of mouse synovial cells in
vitro. MTX clearly inhibited the proliferation of mouse
synovial cells in a dose-dependent manner (Figure 3).
Interestingly, the inhibitory effect of MTX was weakened
by the co-addition of IL-6 + sIL-6R.
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Figure 1 Effect of methotrexate (MTX) in the glucose 6-phosphate isomerase (GPI)-induced arthritis model. Mice were immunized with GPI-
GST emulsified in complete adjuvant. MTX (10 mg/kg) was administered 3 times a week from the first day of immunization. (A) Arthritis score was
assessed as described in the Methods section. Each symbol indicates the mean and standard error (SE) of 8 animals. Statistically significant differences
in clinical scores were analyzed by Wilcoxon’s test (*P < 0.05). SLC19A1 mRNA expressions in (B) whole hind limbs, (C) CD4 T cells, and (D) B cells were
measured by real-time polymerase chain reaction (PCR). (E) IL-6 and (F) TNF-a mRNA expression in whole hind limbs was measured by real-time PCR.
Samples were obtained on day 15. Each bar and error bar indicates the mean and SE of 8 animals. Statistical significance was analyzed by Dunnett’s
multiple comparison test (#P < 0.05) or unpaired t-test (*P < 0.05). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Concomitant use of MTX and anti-IL-6R antibody in GPI-
induced arthritis
Iwanami et al. reported that the development of GPI-
induced arthritis was almost completely blocked by the
injection of MR16-1 on days 0, 3, or 8 after immunization,
whereas injection of MR16-1 on day 14, at the peak of
arthritis, did not ameliorate arthritis, because injection of
MR16-1 on day 14 did not inhibit Th17 induction [17]. A
similar result was obtained in our study; namely, injection
of MR16-1 on days 0 or 5 completely blocked the onset of
arthritis, but the injection on day 10 did not ameliorate
arthritis (data not shown). From these results, we decided
to administer MR16-1 on day 10, because this regimen
can exclude the direct effect of MR16-1 on the progression
of arthritis.
Next, we examined whether the combination use of
MTX and MR16-1 would affect the inhibitory effect
of MTX on GPI-induced arthritis. Surprisingly, although
MR16-1 monotherapy did not reduce arthritis score,
concomitant use of MTX and MR16-1 significantly
reduced the progression of arthritis compared with the
vehicle group or the MTX group (Figure 4A).
To examine whether this phenomenon was induced by
blocking IL-6, we measured concentrations of IL-6 and
SAA in serum on day 15. Serum concentration of IL-6
was significantly elevated in vehicle-treated arthritic mice
compared with intact mice (Figure 4B). Although serum
IL-6 concentration did not significantly change in the
MTX group compared with the vehicle-treated group,
dramatic elevation of serum IL-6 level was observed in
the MR16-1 group and the MTX plus MR16-1 group. It
has been shown that IL-6 induces SAA [24], and because
SAA is a beneficial marker of IL-6 activity, we also mea-
sured the serum level of SAA. Levels of SAA in the vehi-
cle group were increased to 100 times the levels in intact
mice, and were only slightly reduced in MTX-treated
immunized mice. On the other hand, SAA induction was
completely inhibited in the MR16-1 group and the MTX
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Figure 2 Interleukin-6 (IL-6) and methotrexate (MTX) reduced SLC19A1 expression and uptake of MTX into mouse synoviocytes.
Synoviocytes from arthritic mice were cultured for 24 h with (A) IL-6 (1, 10, 100 ng/mL) + soluble IL-6 receptor (sIL-6R) (100 ng/mL), (B) MTX (1, 10,
100 nM), (C) tumor necrosis factor -a (TNF-a) (0.1, 1, 10 ng/mL), or (D) IL-6 (100 ng/mL) + sIL-6R (100 ng/mL), MTX (100 nM), or IL-6 (100 ng/mL) +
sIL-6R (100 ng/mL) + MTX (100 nM). After culturing, cell lysate was collected and the mRNA expression for SLC19A1 was measured by real-time
polymerase chain reaction. (E) Mouse synoviocytes were cultured for 24 h with IL-6 (100 ng/mL) + sIL-6R (100 ng/mL), MTX (100 nM), or IL-6
(100 ng/mL) + sIL-6R (100 ng/mL) + MTX (100 nM). The uptake of Alexa Fluor 488 conjugated MTX (100 nM) was quantified by measuring the
fluorescence emission for each sample. Results are expressed in arbitrary units of fluorescence intensity. Each column and vertical line represents
the mean and standard deviation of triplicate cultures. Statistical significance was analyzed by Dunnett’s multiple comparison test (#P < 0.05) or
unpaired t-test (* P < 0.05).
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plus MR16-1 group (Figure 4C). We also noted that the
body weights in all groups were unchanged throughout
the experiments (data not shown).
The expressions of SLC19A1 mRNA in whole hind
limbs, CD4 T cells and B cells were increased in the
MR16-1 group and in the MTX plus MR16-1 group
compared with those in the vehicle group (Figure 5A-C).
Moreover, the levels of SLC19A1 mRNA expression sig-
nificantly increased in the MTX plus MR16-1 group
compared with those in the MTX group.
Discussion
Several transporters are associated with MTX uptake into
cells, and these are expected to be important in determin-
ing the response and resistance to MTX [15,16]. SLC19A1
is one of the most important transporters by which MTX
is taken up by cells; its expression level therefore, can pre-
dict response to MTX therapy in cancer patients [15,16].
In this study, we examined the relationship between the
efficacy of MTX and the expression of SLC19A1 in an
arthritic animal model. We found that: 1) the expression
of SLC19A1 was significantly reduced in inflamed whole
hind limbs; 2) MTX itself and IL-6 + sIL-6R, but not
TNF-a, directly decreased the expression of SLC19A1 in
synovial cells; 3) MTX and IL-6 + sIL-6R reduced the
uptake of MTX into synovial cells and 4) the efficacy of
MTX on the arthritis score was augmented by concomi-
tant use of anti-IL-6R antibody. These results strongly sug-
gest that the expression level of SLC19A1 is correlated
with the efficacy of MTX in arthritic animals.
MTX is very effective in the therapy of patients with
RA. However, the loss or reduction of its efficacy is a
major problem. Although its precise mechanism is not
fully understood, some reports have mentioned that spe-
cific cell membrane-associated drug efflux transporters,
such as multidrug resistance protein-1 (MRP-1) and
breast cancer resistance protein (BCRP), are induced
upon therapy with MTX [25,26]. In the present study, we
found that MTX reduced the expression of SLC19A1 in
the whole hind limbs of arthritic mice. This mechanism
may also be involved in secondary refractoriness to MTX
in RA patients.
We also found that intracellular concentration of
MTX was significantly lower in IL-6 + sIL-6R-treated
synovial cells than in IL-6-nontreated cells and that the
anti-proliferative effect of MTX was inhibited in the
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Figure 3 Effect of interleukin-6 (IL-6) on methotrexate (MTX)-induced anti-proliferative effect. Synoviocytes from arthritic mice were
cultured for 24 h with methotrexate (0, 10, 100, 1,000 nM) with medium alone or in the presence of IL-6 (100 ng/mL) + soluble IL-6 receptor
(sIL-6R) (100 ng/mL). After culturing, cell proliferation was measured by uptake of bromodeoxyuridine. Statistical significance was analyzed by the
unpaired t-test (*P < 0.05). Each column and vertical line indicates the mean and standard deviation of quadruplicate cultures.
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Figure 4 Effect of concomitant use of methotrexate (MTX) and anti-interleukin-6 receptor (IL-6R) antibody on arthritis score. MTX (10
mg/kg) was administered 3 times a week from the first day of immunization. Rat anti-mouse IL-6R monoclonal antibody (MR16-1) (4 mg/mouse)
was injected on day 10. (A) Arthritis score was assessed as described in the Methods section. Each symbol indicates the mean and standard error
(SE) of 8 to 9 animals. Statistical significance was analyzed by Wilcoxon’s test (P < 0.05, *vs. vehicle; #vs. MTX). Levels of (B) IL-6 and (C) serum
amyloid A (SAA) were measured by ELISA. Sera were obtained on day 15. Each bar and error bar indicates the mean and SE of 8 to 9 animals.
Statistical significance was analyzed by Dunnett’s multiple comparison test (#P < 0.05) or the unpaired t-test (*P < 0.05).
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Figure 5 Effect of concomitant use of methotrexate (MTX) and anti-interleukin-6 receptor (IL-6R) antibody on SLC19A1 expression.
MTX (10 mg/kg) was administered 3 times a week from the first day of immunization. Rat anti-mouse IL-6R monoclonal antibody (4 mg/mouse)
was injected on day 10. SLC19A1 mRNA expression in (A) whole hind limbs, (B) CD4 T cells, and (C) B cells were measured by real-time
polymerase chain reaction. Each bar and error bar indicates the mean and standard error of 8 to 9 animals. Statistical significance was analyzed
by the unpaired t-test (*P < 0.05) or Dunnett’s multiple comparison test (#P < 0.05). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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presence of IL-6 + sIL-6R. MTX enters the cells mainly
via SLC19A1 and effluxes from cells via ATP-binding cas-
sette (ABC) transporters [25,26]. As shown in Figure 2,
IL-6 + sIL-6R inhibited the expression of SLC19A1. More-
over, it is reported that MTX-resistant malignant cells
highly express ABC transporters such as MRP-1 and
BCRP [25,26]. We examined the effect of IL-6 + sIL-6R on
these two ABC transporters, but IL-6 + sIL-6R did not
affect their expression (see Additional file 1). This result
suggests that the decrease in intracellular concentration of
MTX by IL-6 + sIL-6R results from the inhibition of MTX
uptake via reduction of the influx transporter, and not by
accelerated excretion of MTX from cells. MTX undergoes
intracellular polyglutamation by folylpolyglutamate
synthetase [27]. MTX-polyglutamates are kept within cells
for longer periods than MTX itself [28]. In addition, poly-
glutamation increases the affinity of MTX for its target
enzymes such as dihydrofolate reductase, thymidylate
synthase, and 5-aminoimidazole-4-carboxamide ribonu-
cleotide transformylase [29]. MTX-polyglutamates are
converted to MTX by g-glutamylhydrolase [30] and
effluxed from cells by ABC transporters. We examined the
effect of IL-6 + sIL-6R on these enzymes, but found that
IL-6 + sIL-6R did not affect induction of these enzymes
(data not shown).
We demonstrated that the whole hind limbs of
arthritic mice showed lower SLC19A1 expression than
whole hind limbs of normal mice, which was reversed
by IL-6 blockade, and that MTX treatment reduced
SLC19A1 expression in arthritic mice. We also obtained
similar results in an in vitro study using synovial cells
from arthritic mice; namely, IL-6 + sIL-6R and MTX
each reduced SLC19A1 expression in synovial cells, and
the combination of IL-6 + sIL-6R + MTX further
reduced its expression. Although a precise mechanism
for the reduction of SLC19A1 expression by MTX and
IL-6 + sIL-6R is still unknown, our results strongly sug-
gest that IL-6 + sIL-6R and MTX each suppressed
SLC19A1 expression by an independent mechanism. We
are currently planning a study to verify how IL-6 + sIL-
6R and MTX suppress SLC19A1 expression.
IL-6 exerts its biological activities through two mem-
brane molecules, a ligand-binding 80 kDa chain (IL-6R)
and a non-ligand-binding signal transducer gp130 [31].
After binding of IL-6 to membrane-bound IL-6R (mIL-
6R), the IL-6/IL-6R complex associates with gp130, and a
signal is transmitted into the cell. In addition, sIL-6R,
which lacks trans-membrane and cytoplasmic domains,
can also associate with gp130 in the presence of IL-6 and
transduce the signal via gp130. Therefore, both mIL-6R
and sIL-6R play essential roles in IL-6 signaling. In this
study, IL-6 + sIL-6R, but not IL-6 or sIL-6R alone, could
decrease SLC19A1 in synovial cells, suggesting that
synovial cells express gp130 but not mIL-6R. As there is
sufficient sIL-6R in synovial fluid and blood, we think that
the phenomenon seen in vitro in this study is likely to
occur in vivo.
In RA patients as well as in arthritic animals, IL-6
concentration in serum and synovial fluid is higher than
in healthy individuals or patients with osteoarthritis
[32]. Therefore, IL-6-induced reduction of SLC19A1
expression is very likely to occur in patients with RA.
More recently, Takeuchi et al. reported that combina-
tion therapy of anti-IL-6 therapy with tocilizumab and
MTX showed a more remarkable effect as assessed by
the Health Assessment Questionnaire-Disability Index
(HAQ-DI) and by the 28-joint disease activity score
(DAS28) than tocilizumab monotherapy in daily clinical
practice [33]. This result could be partly explained by
enhanced MTX efficacy resulting from reversal of the
decrease in SLC19A1 expression by tocilizumab. Further
studies of the relationship between expression of
SLC19A1 and clinical response after MTX and anti-IL-6
therapy in patients with RA are needed to confirm our
hypothesis.
Serum IL-6 concentration was dramatically up-regu-
lated in the MR16-1-treated groups. We previously
showed that the elevation of IL-6 levels in serum follow-
ing treatment with anti-IL-6R antibodies is due to the
inhibition of IL-6R-mediated clearance of IL-6 from the
blood, and is not the result of induction of IL-6 protein
synthesis to compensate for the IL-6 blockade or release
of free IL-6 from complexes [34]. Moreover, MR16-1
treatment completely inhibited the induction of SAA.
These data clearly demonstrate that IL-6 signaling was
completely inhibited by MR16-1 in this study.
TNF-a antagonists in combination with MTX are
highly effective treatments for severe RA [35]. When
anti-TNF-a antibodies are used in monotherapy, antibo-
dies against the anti-TNF-a antibodies are often
induced. Since antibodies to the anti-TNF-a antibodies
decrease serum levels of the anti-TNF-a antibody and
diminish the therapeutic effects [36-39], MTX combina-
tion is mandatory in treatments with infliximab, adali-
mumab, or golimumab. Of interest, TNF-a-receptor-Fc-
fusion protein (etanercept) has been shown to be effec-
tive for RA even as a monotherapy because antibodies
against etanercept are rarely produced [40]. However, a
recent report has shown that, in MTX-refractory
patients with RA, clinical response is better with etaner-
cept plus MTX than with etanercept alone [41].
Although we showed that TNF-a did not change the
expression of SLC19A1, because TNF-a blockade signif-
icantly reduces serum levels of IL-6 in RA patients [42],
TNF-a blockade may augment the efficacy of MTX in a
manner similar to that of IL-6 blockade.
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Conclusion
In the present study, we demonstrated for the first time
that the expression of the reduced folate transporter
SLC19A1, which is important for MTX uptake into
cells, is strongly related to the efficacy of MTX in an
arthritis model. We also showed that IL-6 reduced the
efficacy of MTX via the inhibition of SLC19A1 expres-
sion; therefore, IL-6 inhibition may improve responsive-
ness to MTX in patients with RA who show inadequate
response to MTX.
Additional material
Additional file 1: A figure showing mRNA expression for multidrug
resistance protein (MRP-1) and breast cancer resistance protein
(BCRP). Synoviocytes from arthritic mice were cultured for 24 h with
interleukin-6 (IL-6) (1, 10, 100 ng/mL) + soluble IL-6 receptor (sIL-6R) (100
ng/mL) or methotrexate (1, 10, 100 nM). After culturing, cell lysate was
collected and mRNA expression for (A) MRP-1 and (B) BCRP was
measured by real-time polymerase chain reaction. Each column and
vertical line represents the mean and standard deviation of triplicate
cultures. Statistical significance was analyzed by Dunnett’s multiple
comparison test or the unpaired t-test. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase.
Author details
1Product Research Department, Fuji-Gotemba Research Laboratories, Chugai
Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513,
Japan. 2Division of Clinical Immunology, Doctoral Program in Clinical
Science, Graduate School of Comprehensive Human Sciences, University of
Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Authors’ contributions
MH was responsible for the acquisition of data, data analysis, interpretation
of data and drafting the manuscript; HY, KT, and MS for the acquisition of
data; IM and TS for drafting the manuscript and MM for the interpretation of
data and drafting the manuscript. All authors read and approved the final
manuscript.
Competing interests
MH, HY, KT, MS, and MM were, or currently are, employed by Chugai
Pharmaceutical., Co., Ltd.
Received: 24 November 2011 Revised: 9 April 2012
Accepted: 30 April 2012 Published: 30 April 2012
References
1. Aletaha D, Smolen JS: DMARD use in early rheumatoid arthritis. Lessons
from observations in patients with established disease. Clin Exp
Rheumatol 2003, 21(5 Suppl 31):S169-S173.
2. Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, Smolen JS:
Survival and effectiveness of leflunomide compared with methotrexate
and sulfasalazine in rheumatoid arthritis: a matched observational study.
Ann Rheum Dis 2003, 62:944-951.
3. Andersen PA, West SG, O’Dell JR, Via CS, Claypool RG, Kotzin BL: Weekly
pulse methotrexate in rheumatoid arthritis. Clinical and immunologic
effects in a randomized, double-blind study. Ann Intern Med 1985,
103:489-496.
4. van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB:
Methotrexate in rheumatoid arthritis: an update with focus on
mechanisms involved in toxicity. Semin Arthritis Rheum 1998, 27:277-292.
5. Cronstein BN: The mechanism of action of methotrexate. Rheum Dis Clin
North Am 1997, 23:739-755.
6. Swierkot J, Szechiński J: Methotrexate in rheumatoid arthritis. Pharmacol
Rep 2006, 58:473-492.
7. Alarcón GS, Tracy IC, Blackburn WD Jr: Methotrexate in rheumatoid
arthritis. Toxic effects as the major factor in limiting long-term
treatment. Arthritis Rheum 1989, 32:671-676.
8. Aletaha D, Smolen JS: The rheumatoid arthritis patient in the clinic:
comparing more than 1,300 consecutive DMARD courses. Rheumatology
(Oxford) 2002, 41:1367-1374.
9. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C: Meta-
analysis of treatment termination rates among rheumatoid arthritis
patients receiving disease-modifying anti-rheumatic drugs. Rheumatology
(Oxford) 2000, 39:975-981.
10. Goldman ID, Lichtenstein NS, Oliverio VT: Carrier-mediated transport of
the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol
Chem 1968, 243:5007-5017.
11. Matherly LH, Goldman DI: Membrane transport of folates. Vitam Horm
2003, 66:403-456.
12. Cronstein BN: Molecular therapeutics. Methotrexate and its mechanism
of action. Arthritis Rheum 1996, 39:1951-1960.
13. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH: Anti-inflammatory
mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis
2001, 60:729-735.
14. Ranganathan P, Eisen S, Yokoyama WM, McLeod HL: Will
pharmacogenetics allow better prediction of methotrexate toxicity and
efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 2003,
62:4-9.
15. Gorlick R, Cole P, Banerjee D, Longo G, Li WW, Hochhauser D, Bertino JR:
Mechanisms of methotrexate resistance in acute leukemia. Decreased
transport and polyglutamylation. Adv Exp Med Biol 1999, 457:543-550.
16. Wong SC, Zhang L, Witt TL, Proefke SA, Bhushan A, Matherly LH: Impaired
membrane transport in methotrexate-resistant CCRF-CEM cells involves
early translation termination and increased turnover of a mutant
reduced folate carrier. J Biol Chem 1999, 274:10388-10394.
17. Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Inoue A, Mihara M, Ohsugi Y,
Mamura M, Goto D, Ito S, Tsutsumi A, Kishimoto T, Sumida T: Crucial role
of the interleukin-6/interleukin-17 cytokine axis in the induction of
arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 2008,
58:754-763.
18. Taylor PC, Williams RO, Maini RN: Anti-TNF alpha therapy in rheumatoid
arthritis–current and future directions. Curr Dir Autoimmun 2000, 2:83-102.
19. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J,
Alecock E, Woodworth T, Alten R, OPTION Investigators: Effect of
interleukin-6 receptor inhibition with tocilizumab in patients with
rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled,
randomised trial. Lancet 2008, 371:987-997.
20. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X,
Li T, Bahrt K, Kelly S, Le Bars M, Genovese MC: The 6-month safety and
efficacy of abatacept in patients with rheumatoid arthritis who
underwent a washout after anti-tumour necrosis factor therapy or were
directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009,
68:1708-1714.
21. Matsumoto I, Zhang H, Yasukochi T, Iwanami K, Tanaka Y, Inoue A, Goto D,
Ito S, Tsutsumi A, Sumida T: Therapeutic effects of antibodies to tumor
necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen
4 immunoglobulin in mice with glucose-6-phosphate isomerase induced
arthritis. Arthritis Res Ther 2008, 10:R66.
22. Okazaki M, Yamada Y, Nishimoto N, Yoshizaki K, Mihara M: Characterization
of anti-mouse interleukin-6 receptor antibody. Immunol Lett 2002,
84:231-240.
23. Mihara M, Urakawa K, Takagi N, Moriya Y, Takeda Y: In vitro and in vivo
biological activities of a novel nonpolyglutamable anti-folate, MX-68.
Immunopharmacology 1996, 35:41-46.
24. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K: IL-6
plays a critical role in the synergistic induction of human serum amyloid
A (SAA) gene when stimulated with proinflammatory cytokines as
analyzed with an SAA isoform real-time quantitative RT-PCR assay
system. Biochem Biophys Res Commun 2004, 314:363-369.
25. van der Heijden JW, Oerlemans R, Tak PP, Assaraf YG, Kraan MC,
Scheffer GL, van der Laken CJ, Lems WF, Scheper RJ, Dijkmans BA,
Jansen G: Involvement of breast cancer resistance protein expression on
Hashizume et al. Arthritis Research & Therapy 2012, 14:R96
http://arthritis-research.com/content/14/2/R96
Page 9 of 10
rheumatoid arthritis synovial tissue macrophages in resistance to
methotrexate and leflunomide. Arthritis Rheum 2009, 60:669-677.
26. Agarwal V, Mittal SK, Misra R: Expression of multidrug resistance-1 protein
correlates with disease activity rather than the refractoriness to
methotrexate therapy in rheumatoid arthritis. Clin Rheumatol 2009,
28:427-433.
27. Baugh CM, Krumdieck CL, Nair MG: Polygammaglutamyl metabolites of
methotrexate. Biochem Biophys Res Commun 1973, 52:27-34.
28. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S,
Drake JC, Jolivet J: Polyglutamation of methotrexate. Is methotrexate a
prodrug? J Clin Invest 1985, 76:907-912.
29. Kumar P, Kisliuk RL, Gaumont Y, Freisheim JH, Nair MG: Inhibition of
human dihydrofolate reductase by antifolyl polyglutamates. Biochem
Pharmacol 1989, 38:541-543.
30. Rhee MS, Wang Y, Nair MG, Galivan J: Acquisition of resistance to
antifolates caused by enhanced gamma-glutamyl hydrolase activity.
Cancer Res 1993, 53(10 Suppl):2227-2230.
31. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T: Molecular
cloning and expression of an IL-6 signal transducer, gp130. Cell 1990,
63:1149-1157.
32. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I,
Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S: Interleukin-6 and soluble
interleukin-6 receptors in the synovial fluids from rheumatoid arthritis
patients are responsible for osteoclast-like cell formation. J Bone Miner
Res 1996, 11:88-95.
33. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Sato E,
Saito K, Kaneko Y, Fukuyo S, Kurasawa T, Hanami K, Kameda H, Yamanaka H:
Clinical, radiographic and functional effectiveness of tocilizumab for
rheumatoid arthritis patients–REACTION 52-week study. Rheumatology
(Oxford) 2011, 50:1908-1915.
34. Uchiyama Y, Yoshida H, Koike N, Hayakawa N, Sugita A, Nishimura T,
Mihara M: Anti-IL-6 receptor antibody increases blood IL-6 level via the
blockade of IL-6 clearance, but not via the induction of IL-6 production.
Int Immunopharmacol 2008, 8:1595-1601.
35. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E:
Indirect comparisons of the efficacy of biological antirheumatic agents
in rheumatoid arthritis in patients with an inadequate response to
conventional disease-modifying antirheumatic drugs or to an anti-
tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011,
70:266-271.
36. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T:
Individualized monitoring of drug bioavailability and immunogenicity in
rheumatoid arthritis patients treated with the tumor necrosis factor
alpha inhibitor infliximab. Arthritis Rheum 2006, 54:3782-3789.
37. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van
Riel PL, Bendtzen K: Formation of antibodies against infliximab and
adalimumab strongly correlates with functional drug levels and clinical
responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745.
38. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT,
Stapel S, Tak PP, Aarden L, Dijkmans B: Development of antiinfliximab
antibodies and relationship to clinical response in patients with
rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715.
39. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF,
Aarden L, Dijkmans BA, Tak PP, Wolbink GJ: Clinical response to
adalimumab: relationship to anti-adalimumab antibodies and serum
adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007,
66:921-926.
40. van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R,
Freundlich B, MacPeek D, Add Enbrel or Replace Methotrexate Study
Investigators: Efficacy and safety of combination etanercept and
methotrexate versus etanercept alone in patients with rheumatoid
arthritis with an inadequate response to methotrexate: the ADORE
study. Ann Rheum Dis 2006, 65:1478-1483.
41. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T,
Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, Takeuchi T:
Continuation of methotrexate resulted in better clinical and
radiographic outcomes than discontinuation upon starting etanercept in
patients with rheumatoid arthritis: 52-week results from the JESMR
Study. J Rheumatol 2011, 38:1585-1592.
42. Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL,
Barerra P: Influence of anti-tumour necrosis factor therapy on
cardiovascular risk factors in patients with active rheumatoid arthritis.
Ann Rheum Dis 2005, 64:303-305.
doi:10.1186/ar3821
Cite this article as: Hashizume et al.: Interleukin-6 regulates anti-arthritic
effect of methotrexate via reduction of SLC19A1 expression in a mouse
arthritis model. Arthritis Research & Therapy 2012 14:R96.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hashizume et al. Arthritis Research & Therapy 2012, 14:R96
http://arthritis-research.com/content/14/2/R96
Page 10 of 10
